{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["42(8)"],"submitter":["Marnat G"],"pubmed_abstract":["<h4>Background and purpose</h4>Rescue endovascular and pharmacologic approaches are increasingly being adopted after recanalization failure of acute large-vessel occlusion strokes with mechanical thrombectomy, with encouraging results. The safety and efficacy of glycoprotein IIb/IIIa inhibitors in ischemic stroke have been investigated, though cangrelor, a recent intravenous P2Y12-receptor inhibitor with a rapid onset/offset of action and a short half-life, may be a valuable option. We compared the safety and efficacy of cangrelor with those of glycoprotein IIb/IIIa inhibitors for refractory occlusions.<h4>Materials and methods</h4>We performed a retrospective analysis of the ongoing prospective, multicenter, observational Endovascular Treatment in Ischemic Stroke Registry in France betwee"],"journal":["AJNR. American journal of neuroradiology"],"pagination":["1452-1457"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8367600"],"repository":["biostudies-literature"],"pubmed_title":["A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions."],"pmcid":["PMC8367600"],"pubmed_authors":["Delvoye F","Desilles JP","Gory B","Lapergue B","Darcourt J","Marnat G","Gariel F","Chalumeau V","Finitsis S","Consoli A","Clarencon F","Mazighi M","Dargazanli C","Bourcier R","ETIS Investigators","Elhorany M","Richard S","Sibon I"],"additional_accession":[]},"is_claimable":false,"name":"A Multicenter Preliminary Study of Cangrelor following Thrombectomy Failure for Refractory Proximal Intracranial Occlusions.","description":"<h4>Background and purpose</h4>Rescue endovascular and pharmacologic approaches are increasingly being adopted after recanalization failure of acute large-vessel occlusion strokes with mechanical thrombectomy, with encouraging results. The safety and efficacy of glycoprotein IIb/IIIa inhibitors in ischemic stroke have been investigated, though cangrelor, a recent intravenous P2Y12-receptor inhibitor with a rapid onset/offset of action and a short half-life, may be a valuable option. We compared the safety and efficacy of cangrelor with those of glycoprotein IIb/IIIa inhibitors for refractory occlusions.<h4>Materials and methods</h4>We performed a retrospective analysis of the ongoing prospective, multicenter, observational Endovascular Treatment in Ischemic Stroke Registry in France betwee","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Aug","modification":"2025-04-26T16:36:24.681Z","creation":"2025-04-06T15:13:15.51Z"},"accession":"S-EPMC8367600","cross_references":{"pubmed":["34117019"],"doi":["10.3174/ajnr.a7180","10.3174/ajnr.A7180"]}}